newsroom

Panhwar Jet Inc. Receives $10 Million Series A Funding From Valkyrie Group

August 3, 2021 Panhwar Jet Inc, a Newport Beach, CA based startup, is proud to announce the receipt of $10 Million in Series A funding from Valkyrie Group. Valkyrie Group, a Utah based venture capital firm, also plans to raise an additional $100 Million Series B round of capital to accelerate the growth of the new venture.

Panhwar Jet is designing and building the world's first all-electric, self-charging luxury business aircraft. The groundbreaking self-charging technology will eclipse the competition in the electric aircraft industry. Current battery density does not allow other electric aircraft to fly beyond 2 hours total flight time. However, the disruptive self-charging technology invented by Panhwar Jet will allow their aircraft to fly up to 12 hours without touching down.

Panhwar Jet’s patented technology has solved the battery problem that others could not. Panhwar Jet is also determined to provide the best flight experience by using clean, sustainable energy which will create a new future of aviation where speed and range have no limitations.

Chad Swensen, Founder and Managing Partner of Valkyrie, "We’re excited about the innovation that Panhwar Jet is bringing to a large global market. We are fully committed to supporting Panhwar Jet realize the full potential of such a revolutionary technology in fully electric aviation."

"We're excited to collaborate with Valkyrie Group as our strategic capital partner," says Ms. Ayisha Fareed, Chairman, and CEO of Panhwar Jet. Fareed commented, "Valkyrie and Panhwar Jet share the passion, team spirit, background, and experience that will disrupt the electric aircraft industry."

According to Fareed, “This investment will allow Panhwar Jet to enhance the specifications of "ElectroBird," our first two-seater all-electric plane. We will unveil our technology to the world while attempting to achieve several world records in electric aviation. All records will be verified by third partly review. The announcement of the date will be in late October 2021.”

Valkyrie Group Places Big Bet With Hair Growth Pharmaceutical Firm Aneira Pharma, Inc.

$25 million investment from Valkyrie will support clinical trials with ground-breaking, prescription-based hair growth product for men and women

Investment and growth firm Valkyrie Group ("Valkyrie") has committed an investment of $25 million into Aneira Pharma, Inc. ("Aneira") to be used toward completion of its clinical trials. Aneira is developing a ground-breaking, prescription-based hair growth product for men and women experiencing hair loss. Valkyrie's decision to invest is the result of their experience with Aneira's founders and their successful backgrounds in building innovating products. It also meets Valkyrie's commitment to funding straightforward business investment strategies.

Chad Swensen, Founder and Managing Partner of Valkyrie, noted, "The untapped demand potential for a product like Aneira's is significant, particularly as we understand that the global hair loss market will continue to grow and is expected to exceed $12 billion in the next few years."

Valkyrie co-founding partner and former Goldman Sachs global investor Mark McGoldrick agrees. "This product can be a game-changer offering in the multi-billion-dollar hair growth market which today offers limited remedies for hair loss. Our partnership with Aneira allows us to play an integral role with this exciting company and adopt a straightforward investment strategy in an industry with an annual compounded growth rate that exceeds 5%."

The Aneira product currently in development, promises to produce results of newer, thicker and darker hair growth without unwanted side effects. When approved, the hair growth product will be Aneira's first product to market, although not the only product in their pipeline. The Company has plans for additional hair growth products for the underserved, but large markets. These include products being developed to regrow hair for patients that have lost hair due to illness and/or hair loss disorders. Additionally, Aneira is developing a formula for eyebrow growth and eyebrow thickening.

Aneira was founded by veteran biotech/pharmaceutical executives with a wide range of expertise. Co-founders John Wurst and Kenton Abel, Ph.D., are patent attorneys who have experience with both start-up and established biotech/pharmaceutical companies. Wurst served as lead patent attorney for LatisseÆ and other hair growth products before co-founding Aneira.

"We're pleased to have Valkyrie as our capital partner," Wurst said. "Valkyrie's extensive background and team give us the required capital and experience to help drive the expansive short-term and long-term growth of the company."

Abel formerly oversaw the patent portfolio and strategy for Botox® and was a co-founder of Bonti, Inc., a company acquired by Allergan for $195 million.